FDA naming proposal would decrease competition, FTC says

The staffs of three Federal Trade Commission offices argue that a Food and Drug Administration proposal on naming certain biological products could cause decreased price competition. The FDA is proposing that on labels of certain biologic products — medical products often derived from natural sources — there must be a